Arcus Biosciences Inc

For the period ended Dec 31, 2024. Filed Feb 25, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 25, 2025

RCUS$18.95+3.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

December 31, 2024 and 2023

(In millions, except per share amounts)

	December 31,
	2024	2023
ASSETS
Current assets:
Cash and cash equivalents	$150	$127
Marketable securities	828	632
Receivable from collaboration partners ($6 and $20 from a related party)	20	38
Prepaid expenses and other current assets	18	34
Total current assets	1,016	831
Long-term marketable securities	14	107
Property and equipment, net	47	51
Other noncurrent assets ($— and $6 from a related party)	73	106
Total assets	$1,150	$1,095
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$18	$17
Deferred revenue ($85 and $84 to a related party)	85	91
Other current liabilities	123	76
Total current liabilities	226	184
Deferred revenue, noncurrent ($234 and $291 to a related party)	234	307
Long-term debt	48	—
Other noncurrent liabilities	157	142
Commitments (Note 17)
Stockholders’ equity:
Common stock and additional paid-in capital: $0.0001 par value per share; 400.0 shares authorized; 92.2 shares in 2024 and 75.5 shares in 2023 issued and outstanding	1,617	1,311
Accumulated deficit	(1,132)	(849)
Total stockholders’ equity	485	462
Total liabilities and stockholders’ equity	$1,150	$1,095

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.